X-77683623-G-C
Position:
Variant summary
Our verdict is Benign. Variant got -19 ACMG points: 1P and 20B. PP2BP4_StrongBP6_Very_StrongBS1BS2
The NM_000489.6(ATRX):āc.1633C>Gā(p.Gln545Glu) variant causes a missense change. The variant allele was found at a frequency of 0.00115 in 1,209,806 control chromosomes in the GnomAD database, including 14 homozygotes. There are 366 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 12/17 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Genomes: š 0.0059 ( 3 hom., 175 hem., cov: 22)
Exomes š: 0.00067 ( 11 hom. 191 hem. )
Consequence
ATRX
NM_000489.6 missense
NM_000489.6 missense
Scores
2
13
Clinical Significance
Conservation
PhyloP100: 3.95
Genes affected
ATRX (HGNC:886): (ATRX chromatin remodeler) The protein encoded by this gene contains an ATPase/helicase domain, and thus it belongs to the SWI/SNF family of chromatin remodeling proteins. This protein is found to undergo cell cycle-dependent phosphorylation, which regulates its nuclear matrix and chromatin association, and suggests its involvement in the gene regulation at interphase and chromosomal segregation in mitosis. Mutations in this gene are associated with X-linked syndromes exhibiting cognitive disabilities as well as alpha-thalassemia (ATRX) syndrome. These mutations have been shown to cause diverse changes in the pattern of DNA methylation, which may provide a link between chromatin remodeling, DNA methylation, and gene expression in developmental processes. Multiple alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -19 ACMG points.
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), ATRX. . Gene score misZ 3.1025 (greater than the threshold 3.09). GenCC has associacion of gene with alpha thalassemia-X-linked intellectual disability syndrome, ATR-X-related syndrome, intellectual disability-hypotonic facies syndrome, X-linked, 1.
BP4
Computational evidence support a benign effect (MetaRNN=0.004659444).
BP6
Variant X-77683623-G-C is Benign according to our data. Variant chrX-77683623-G-C is described in ClinVar as [Benign]. Clinvar id is 93132.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-77683623-G-C is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.0059 (660/111866) while in subpopulation AFR AF= 0.0201 (619/30822). AF 95% confidence interval is 0.0188. There are 3 homozygotes in gnomad4. There are 175 alleles in male gnomad4 subpopulation. Median coverage is 22. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 3 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATRX | NM_000489.6 | c.1633C>G | p.Gln545Glu | missense_variant | 9/35 | ENST00000373344.11 | NP_000480.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATRX | ENST00000373344.11 | c.1633C>G | p.Gln545Glu | missense_variant | 9/35 | 1 | NM_000489.6 | ENSP00000362441.4 |
Frequencies
GnomAD3 genomes AF: 0.00590 AC: 660AN: 111814Hom.: 3 Cov.: 22 AF XY: 0.00511 AC XY: 174AN XY: 34036
GnomAD3 genomes
AF:
AC:
660
AN:
111814
Hom.:
Cov.:
22
AF XY:
AC XY:
174
AN XY:
34036
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00161 AC: 293AN: 182434Hom.: 2 AF XY: 0.00104 AC XY: 70AN XY: 67388
GnomAD3 exomes
AF:
AC:
293
AN:
182434
Hom.:
AF XY:
AC XY:
70
AN XY:
67388
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000666 AC: 731AN: 1097940Hom.: 11 Cov.: 33 AF XY: 0.000526 AC XY: 191AN XY: 363338
GnomAD4 exome
AF:
AC:
731
AN:
1097940
Hom.:
Cov.:
33
AF XY:
AC XY:
191
AN XY:
363338
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00590 AC: 660AN: 111866Hom.: 3 Cov.: 22 AF XY: 0.00513 AC XY: 175AN XY: 34098
GnomAD4 genome
AF:
AC:
660
AN:
111866
Hom.:
Cov.:
22
AF XY:
AC XY:
175
AN XY:
34098
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
67
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
211
ClinVar
Significance: Benign
Submissions summary: Benign:8Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | GeneDx | Aug 21, 2018 | - - |
Likely benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
not specified Benign:2Other:1
Benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jul 07, 2017 | - - |
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 26, 2012 | - - |
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Alpha thalassemia-X-linked intellectual disability syndrome Benign:2
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
Inborn genetic diseases Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 14, 2017 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
.;.;T;T;.
FATHMM_MKL
Benign
D
LIST_S2
Uncertain
D;.;T;T;D
MetaRNN
Benign
T;T;T;T;T
MetaSVM
Benign
T
PrimateAI
Benign
T
PROVEAN
Benign
N;N;.;.;.
REVEL
Benign
Sift
Uncertain
D;D;.;.;.
Sift4G
Benign
T;T;T;.;T
Polyphen
B;.;.;.;.
Vest4
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at